Application No. 16/908,426
`Response to Non-Final Office Action Mailed April 1, 2024
`
`AMENDMENTS TO THE CLAIMS
`
`Listing of the Claims
`
`1.-30. (Canceled).
`
`31. (Currently Amended) A kit comprising:
`
`a. a container comprising a monotherapeutic pharmaceutical composition, the
`
`monotherapeutic pharmaceutical composition comprising:
`
`i. a sole ophthalmic agent, wherein the sole ophthalmic agentis atropine or
`
`atropine sulfate, and wherein the atropine or atropine sulfate is provided at about 0.01
`
`mg/g to about 0.5 mg/g;
`
`ii. water;
`
`iit. a buffer to provide a pH from about 4.8 to about 5.8 [[6.4]], wherein the
`
`buffer comprises a buffering agent selected from a citrate buffering agent and an acetate
`
`buffering agent;
`
`iv. a tonicity adjusting agent; and
`
`v. aviscosity agent; and
`
`b. instructions for use.
`
`32. (Previously Presented) The kit of claim 31, wherein the atropine or atropine sulfate is
`
`present in the monotherapeutic pharmaceutical composition at a concentration of from about
`
`0.01 mg/g to about 0.3 mg/g or from about 0.1 mg/g to about 0.2 mg/g.
`
`33. (Previously Presented) The kit of claim 31, wherein the atropine or atropine sulfate is
`
`present in the monotherapeutic pharmaceutical composition at a concentration of about 0.1 mg/g,
`
`about 0.2 mg/g, about 0.25 mg/g, about 0.3 mg/g, about 0.4 mg/g, or about 0.5 mg/g.
`
`34. (Currently Amended) Thekit of claim 31, wherein the buffer further comprises a
`
`
`
`buffering agent selected from a borate, a borate-polyol complex,[[,]]a-eitrate-agent—anbuffering
`
`
`
`
`
`acetate-bufferingagent,a carbonate buffering agent, an organic buffering agent, an amino acid
`
`buffering agent, or a combinationthereof.
`
`35. (Cancelled).
`
`36. (Canceled).
`
`37. (Previously Presented) The kit of claim 31, wherein the tonicity adjusting agent
`
`comprises a halide salt of a monovalentcation.
`
`-3-
`
`Atty. Docket No.: 46682-701.317
`
`

`

`Application No. 16/908,426
`Response to Non-Final Office Action Mailed April 1, 2024
`
`38. (Canceled).
`
`39. (Previously Presented) The kit of claim 31, wherein the viscosity agent comprises
`
`hydroxyethyl cellulose, hydroxypropyl cellulose, or hydroxypropylmethyl-cellulose (HPMC).
`
`40. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition is substantially free of a preservative.
`
`41. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition comprises less than about 1% ofa preservative.
`
`42. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition further comprises a preservative.
`
`43. (Previously Presented) The kit of claim 42, wherein a concentration of the
`
`preservative is from about 0.0001% to about 1%.
`
`44. (Currently Amended) The kit of claim 42, wherein the preservative is selected from
`
`the group consisting of benzalkonium chloride, cetrimonium, sodium perborate, stabilized
`
`oxychloro complex, polyquaterntum-1, chlorobutanol, edetate disodium, polyhexamethylene
`
`biguanide, erand combinationsthereof.
`
`45. (Currently Amended) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition is essentially free of procaine and benactyzine, er and
`
`pharmaceutically acceptable salts thereof.
`
`46.-48. (Canceled).
`
`49. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition is a solution.
`
`50. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical compositionissterile.
`
`51. (Previously Presented) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition further comprises a stabilizing agent.
`
`52. (Previously Presented) The kit of claim 51, wherein the stabilizing agentis selected
`
`from the group consisting of glycerol, methionine, monothioglycerol, ethylenediaminetetraacetic
`
`acid (EDTA), ascorbic acid, polysorbate 80, polysorbate 20, arginine, heparin, dextran sulfate,
`
`cyclodextrins, pentosan polysulfate, magnesium, zinc, and combinationsthereof.
`
`53. (Previously Presented) The kit of claim 52, wherein the stabilizing agent is EDTA.
`
`4.
`
`Atty. Docket No.: 46682-701.317
`
`